Skip to main content
Health Industries Research Companies (HIRC)
My Account
Services
Managed Markets
Organized Providers
Best Programs and Best People
Specialty Pharmaceuticals
Managed Oncology
Free Research Highlights
HIRC Webinar Series
HIRC Special Report Series
About Us
Careers
Contact Us
Register/Login
|
Newsfeed
Search form
Search
You are here
HIRC Blog
Related Posts on Trends in Specialty and Oncology
Latest Blog Posts
Aetna and Humana's Tainted Love; Cigna-Anthem Relationship Status? It's Complicated.
ACA Repeal a Ticking Time Bomb
Is ICER Making an Impact?
Pharmaceutical Stocks Soar in Post-Election Tailwind
Presidential Election Unlikely to Effect Drug Prices; Instead Watch Out for Proposition 61
Walgreens and Prime Therapeutics Form Alliance to Battle Drug Costs
MACRA: Hurricane or Tropical Storm?
Biosimilars are Same Same but Different: CVS Chooses Eli Lilly’s Biosimilar Over Sanofi’s LANTUS
The First US Biosimilar Makes Its Debut... Will it Succeed?
2016 PBM Formulary Exclusion Lists
Pages
« first
‹ previous
1
2
3
next ›
last »
Blog Categories
Trends in Health Care
Aetna and Humana's Tainted Love; Cigna-Anthem Relationship Status? It's Complicated.
Is ICER Making an Impact?
Pharmaceutical Stocks Soar in Post-Election Tailwind
Health Care Reform
ACA Repeal a Ticking Time Bomb
MACRA: Hurricane or Tropical Storm?
Industry News
Presidential Election Unlikely to Effect Drug Prices; Instead Watch Out for Proposition 61
2016 PBM Formulary Exclusion Lists
Walgreens and Prime Therapeutics Form Alliance to Battle Drug Costs
Trends in Specialty and Oncology
Biosimilars are Same Same but Different: CVS Chooses Eli Lilly’s Biosimilar Over Sanofi’s LANTUS
The First US Biosimilar Makes Its Debut... Will it Succeed?
Pages
« first
‹ previous
1
2
3
next ›
last »
For more information, please call Health Industries Research at (408) 884-8560
